ECOG-ACRIN Biospecimen Bank to Support NCTN

项目摘要 ECOG-ACRIN（EA）代表ECOG和ACRIN的合并，以形成一个合作小组， 从癌症治疗到癌症治疗， 通过对晚期疾病及其影响的管理，预防和早期发现。本申请 支持EA中央生物储存库和病理学的基础设施和银行业务 设施（EA CBPF），一个高度协作，高效和有影响力的生物储存库， 整合五个NCI国家临床试验网络（NCTN）生物样本库，包括一个目前 完成过渡。将生物贮藏库活动整合到EA CBPF中， 通过集中和继续标准和创新的生物储存库活动， 开发新的癌症预测生物标志物和治疗方法的能力。EA CBPF将 继续得到EA生物统计和数据管理中心（BDMC）、运营办公室、 其他NCTN单位，NCI赞助的项目和研究人员，以及NCI。EA CBPF的目标是确保 收集、储存和分发从癌症患者中获得的注释良好的人类生物标本 参与NIH/NCI和NCTN NCI资助的临床治疗试验。EA CBPF的目标1是收集， 处理、储存、分类和分配恶性和非恶性组织、细胞、血液和其他流体 样本及其衍生物（例如，组织来源的和无细胞的DNA和RNA、蛋白质、外来体和 根据NCI的“最佳实践”， 生物标本资源”，并将标本与相关的临床、病理、免疫学和 NCTN计划中的分子数据;目标2是开发和利用常规和创新 生物标本资源，将有助于成功完成NCTN支持的临床试验， 完整的生物标志物和相关的相关研究，以促进新的生物标志物驱动的发展 个性化的癌症治疗策略;目标3是发展执行经典和 EA临床试验中组织、细胞、血液和其他体液样本的分子方法学 病人，包括计划未来巩固基于功能，并提供专家 与领导相关NCTN的调查人员密切合作，对调查结果进行解释 目的4是协助NIH/NCI NCTN和NCORP内外的研究人员， 通过积极参与和领导高优先级项目， 作为NCTN导航服务和癌症免疫监测中心（CIMAC），以及 积极参与NCI集团银行委员会（GBC）的生物储存协调活动 和NIH/NCI支持的样本库组织。

Project Summary ECOG-ACRIN (EA) represents the merger of ECOG and ACRIN to form a cooperative group focused on practice-changing clinical and translational research across the cancer care continuum from cancer prevention and early detection, through the management of advanced disease and its impact. This application is to support the infrastructure and banking operations for the EA Central Biorepository and Pathology Facility (EA CBPF), a highly collaborative, productive and impactful biorepository resulting from the consolidation of five NCI National Clinical Trials Network (NCTN) Biospecimen Banks, including one currently finalizing transition. The consolidation of biorepository activities into EA CBPF has significantly impacted operations by centralizing and continuing the standard and innovative biorepository activities and enhancing capabilities to develop novel predictive biomarkers and therapeutic approaches in cancer. EA CBPF will continue being assisted by the EA Biostatistics and Data Management Center (BDMC), Operations Offices, other NCTN units, NCI-sponsored programs and investigators, and the NCI. The goal of EA CBPF is to ensure the collection, storage, and distribution of well-annotated human biospecimens, procured from cancer patients participating in the NIH/NCI and NCTN NCI-funded clinical treatment trials. EA CBPF's Aim 1 is to collect, process, store, catalog, and distribute malignant and non-malignant tissues, cells, blood, and other fluid specimens and their derivatives (e.g., tissue-derived and cell free DNA and RNA, proteins, exosomes and circulating tumor cells) from patients enrolled in EA clinical trials following the NCI's “Best Practices for Biospecimen Resources” and to link the specimens to relevant clinical, pathologic, immunological and molecular data within the NCTN program; Aim 2 is to develop and utilize both routine and innovative biospecimen resources that will aid in the successful completion of NCTN-supported clinical trials based on integral biomarkers and of related correlative studies to promote the development of novel biomarker-driven personalized cancer therapeutic strategies; Aim 3 is to develop capabilities for performing classic and molecular methodologies on tissue, cell, blood, and other body fluid–based specimens from EA clinical trial patients, including planned future consolidation of specimen-based functions, and provide expert interpretation of the findings in close collaboration with the investigators leading the related NCTN- supported clinical trials; and Aim 4 is to assist investigators outside and within the NIH/NCI NCTN and NCORP to access biospecimens for research by participating actively, and leading efforts in high priority programs such as the NCTN Navigator services and the Center for Immune Monitoring of Cancer (CIMAC), as well as contributing actively to the biorepository harmonization activities of the NCI Group Banking Committee (GBC) and NIH/NCI-supported specimen banking organizations.